The efficacy of aripiprazole in treatment-resistant Tourette's syndrome: A case report Tedaviye dirençli Tourette bozukluǧunda aripiprrazole yanit: Bir olgu sunumu
Klinik Psikofarmakoloji Bulteni, cilt.19, sa.SUPPL. 1, 2009 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Özet
- Cilt numarası: 19 Sayı: SUPPL. 1
- Basım Tarihi: 2009
- Dergi Adı: Klinik Psikofarmakoloji Bulteni
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Anahtar Kelimeler: Adolescent, Aripiprazole, Child, Tourette's syndrome
- Eskişehir Osmangazi Üniversitesi Adresli: Hayır
Özet
Objective: Tourette's syndrome (TS) is an important childhood-onset neuropsychiatric disorder that is characterized by non-rhythmic, sudden, rapid, involuntary, repetitive multiple motor tics and at least one vocal (phonic) tic. Ideal anti-tic treatments are not presently available. Several typical neuroleptics frequently used for treatment of TS, have potentially serious side-effects. To report a lasting improvement obtained with a new drug, aripiprazole that acts modulating both dopaminergic and serotoninergic neurotransmission. A search of literature reveals data on aripiprazole's use in the adult population with limited research in the child and adolescent age group. In this case report, we aim to share our experience with patient with Tourette's Syndrome, who had persistent symptoms despite the use of at least one psychotropic agent. We also aim to provide data on the efficacy of aripiprazole in Tourette's Syndrome in addition to its use in adolescent age group. Method: The effectiveness and side effects of aripiprazole were evaluated with the Clinical Global Impression (CGI) Scale and, Chouinard and Ross-Chouinard's Extrapyramidal Symptom Rating Scale, The UKU Side Effect Rating Scale in addition to the vital and other biological parameters. Results: We report on an 16 year old male patient who demonstrated motor and vocal tics as main symptom for 3,5 years. We treated him with aripiprazole at 10 mg daily dose. Significant improvement was assessed in CGI for the patient between baseline and week 4. End of 4th. week fatique, minimal weight loss was observed at UKU-SERC. No significant side effect, extrapyramidal symptom and no differences in vital and other biological parameters was observed between the baseline and end point. Conclusions: This case demonstrates that a relatively low dose of aripiprazole can be used to control tic symptoms effectively in children and adolescents with TD and chronic tic disorders without causing significant side effect.